| Bioactivity | Elipovimab is a potent broadly neutralizing HIV-1 antibody for the targeted elimination of HIV-infected cells[1] |
| Name | Elipovimab |
| CAS | 2101210-43-7 |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Caroline Thue Hvilsom, et al. TLR-Agonist Mediated Enhancement of Antibody-Dependent Effector Functions as Strategy For an HIV-1 Cure. Front Immunol. 2021 Sep 23;12:704617. |